Sou Hu Cai Jing·2025-12-20 00:32Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong operational performance and potential investment interest [3]. Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, a year-on-year increase of 48.75% [3]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [3]. - The net profit excluding non-recurring items was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [3]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable increase of 109.51% year-on-year [3]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, showing a significant rise of 531.12% year-on-year [3]. - The quarterly net profit excluding non-recurring items was 74.52 million yuan, up 439.4% year-on-year [3]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [3]. - The gross profit margin is reported at 67.27% [3]. Market Activity - As of December 19, 2025, Spring Medical's stock closed at 24.84 yuan, reflecting a 3.76% increase [1]. - The trading volume on December 19 was 17,800 hands, with a total transaction amount of 44.1792 million yuan [1]. - The net inflow of main funds was 219,000 yuan, accounting for 0.5% of the total transaction amount, while retail investors saw a net inflow of 251,610 yuan, representing 5.7% of the total [1]. - Over the past five days, the financing buy amounted to 1.558 million yuan, while financing repayment was 2.6855 million yuan, resulting in a net repayment of 1.1275 million yuan [2]. - The financing and securities balance is reported at 31.0494 million yuan [2]. Analyst Ratings - In the last 90 days, 9 institutions have rated Spring Medical, with 8 giving a "buy" rating and 1 an "increase" rating [3]. - The average target price set by institutions over the past 90 days is 31.8 yuan [3].